NeoGenomics (NEO)
(Delayed Data from NSDQ)
$13.85 USD
-0.18 (-1.28%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $14.15 +0.30 (2.17%) 6:52 PM ET
2-Buy of 5 2
C Value A Growth D Momentum B VGM
NeoGenomics (NEO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$21.10 | $30.00 | $18.00 | 50.39% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for NeoGenomics comes to $21.10. The forecasts range from a low of $18.00 to a high of $30.00. The average price target represents an increase of 50.39% from the last closing price of $14.03.
Analyst Price Targets (10)
Broker Rating
NeoGenomics currently has an average brokerage recommendation (ABR) of 1.58 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 1.58 a month ago based on 12 recommendations.
Of the 12 recommendations deriving the current ABR, eight are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 66.67% and 8.33% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 8.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 8 | 8 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.58 | 1.58 | 1.58 | 1.58 | 1.58 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/22/2024 | SVB Securities | Puneet Souda | Strong Buy | Strong Buy |
3/1/2024 | Stephens | Mason Carrico | Strong Buy | Strong Buy |
2/27/2024 | BTIG | Mark Massaro | Strong Buy | Strong Buy |
2/26/2024 | Piper Sandler | David M Westenberg | Strong Buy | Strong Buy |
2/21/2024 | William Blair | Andrew F Brackmann | Strong Buy | Strong Buy |
2/21/2024 | Raymond James | Andrew Cooper | Hold | Hold |
12/28/2023 | Needham & Company | Michael Matson | Moderate Buy | Moderate Buy |
8/7/2023 | The Benchmark Company | Bruce D Jackson | Hold | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.58 |
ABR (Last week) | 1.58 |
# of Recs in ABR | 12 |
Average Target Price | $21.10 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 69 of 252 |
Current Quarter EPS Est: | -0.03 |